Press Releases

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2020 financial results before the open of the market on

The T-SPOT.TB test is now the only interferon-gamma release assay (IGRA) cleared for use in children ages two and upwards in the United States OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global,

OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has entered into an extensive research collaboration with Public Health England (PHE), an

Second quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 Ended the quarter with approximately $165 million of cash and cash equivalents Third quarter revenue estimated to be between $18 - $19 million OXFORD, United Kingdom and

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2020 financial results before the open of the market on

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-term agreement to supply its T-SPOT. TB test and associated accessories to the Stop TB Partnership - Global

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit.

First quarter revenue of $13.9 million, a decrease of 6% compared to prior year period, due to the impact of COVID-19 in China Gross margins expanded 270bps to 74% Ended the quarter with $166 million of cash and cash equivalents OXFORD, United Kingdom and MARLBOROUGH, Mass., May 05, 2020 (GLOBE

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on